Author

I. D. Ferguson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 7 Assay:proteomics· 5 Approach:experimental assay· 4 Approach:statistical model· 4 Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

A. P. Wiita· 5 shared Y.-H. T. Lin· 4 shared C. Driessen· 3 shared M. C. Mariano· 3 shared B. C. Hann· 2 shared J. L. Wolf· 2 shared M. A. Nix· 2 shared M. Hale· 2 shared

Activity by Year

2019-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

A. P. Wiita

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Mitochondrial Raf1 Regulates Glutamine Catabolism

R. L. Shanderson, I. D. Ferguson, Z. Siprashvili, L. Ducoli, A. Li, W. Miao, S. Srinivasan, M. G. Velasco, Y. Li, J. Ye, P. Khavari

This paper identifies Raf1 within mitochondria where it interacts with GLS to regulate glutamine catabolism and tumorigenesis, independent of MAPK signaling.

bioRxiv · Mar 8, 2024Cancer Biology

SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants bind human ACE2 with increased affinity

P. Khavari, M. Ramanathan, I. D. Ferguson, W. Miao

This study measures the binding affinity of SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants to human ACE2 using MST, finding increased binding for both variants compared to the original SARS-CoV-2 RBD.

bioRxiv · Feb 22, 2021Pathology

Defining the cell surface proteomic landscape of multiple myeloma reveals immunotherapeutic strategies and biomarkers of drug resistance

I. D. Ferguson, B. P. Escobar, S. T. Tuomivaara, Y.-H. T. Lin, M. A. Nix, K. K. Leung, M. Hale, P. Choudhry, A. Lopez-Girona, E. Ramos, S. W. Wong, J. L. Wolf, T. G. Martin, N. Shah, S. Vandenberg, , A. P. Wiita

This study defines the myeloma cell surface proteome, identifies therapeutic targets and resistance biomarkers, and presents a miniaturized surface proteomics protocol.

bioRxiv · Jan 17, 2021Cancer Biology

Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma

I. D. Ferguson, Y.-H. T. Lin, C. Lam, H. Shao, M. Hale, K. M. Tharp, M. C. Mariano, V. Steri, D. Wang, P. Phojanokong, S. T. Tuomivaara, B. Hann, C. Driessen, B. V. Ness, J. E. Gestwicki, A. P. Wiita

This study identifies allosteric HSP70 inhibitors that overcome proteasome inhibitor resistance in multiple myeloma by targeting mitochondrial HSPA9 and disrupting mitoribosome stability.

bioRxiv · Apr 21, 2020Cancer Biology

Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis

V. Sarin, K. Yu, I. D. Ferguson, O. Gugliemini, M. A. Nix, B. C. Hann, M. Sirota, A. P. Wiita

This study evaluates how well multiple myeloma cell lines represent patient tumors using transcriptomic correlation analysis, finding significant variation in their similarity to patient tumors.

bioRxiv · Nov 20, 2019Cancer Biology

Integrated Phosphoproteomics and Transcriptional Classifiers Reveal Hidden RAS Signaling Dynamics in Multiple Myeloma

Y.-H. T. Lin, G. P. Way, B. G. Barwick, M. C. Mariano, M. Marcoulis, I. D. Ferguson, C. Driessen, L. H. Boise, C. S. Greene, A. P. Wiita

The paper uses phosphoproteomics and transcriptomics to analyze RAS signaling in multiple myeloma, identifying distinct signaling patterns and clinical outcomes associated with NRAS and KRAS mutations.

bioRxiv · Feb 28, 2019Cancer Biology

Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma

H. H.-L. Huang, I. D. Ferguson, A. M. Thornton, C. Y. T. Lam, Y.-H. T. Lin, P. Bastola, P. Choudhry, M. C. Mariano, M. D. Marcoulis, J. Malato, P. Phojanakong, T. G. Martin, J. L. Wolf, S. W. Wong, N. Shah, , A. P. Wiita

The paper shows proteasome inhibitors modulate splicing in multiple myeloma, revealing spliceosome inhibition as a therapeutic target.

bioRxiv · Feb 3, 2019Cancer Biology